Paris Aesthetician, 38 Years: "Forty American Dermatologists. Combined Centuries of Training. Not One Could Answer the Question I Asked About a Sudden-Crepey-Arm Patient from the Back Row"

My name is Anne Beaumont. I have practiced clinical aesthetics in Paris for thirty-eight years. I have attended dermatology conferences in eight countries: France, Italy, Germany, Switzerland, Austria, the United Kingdom, the United States, and Canada. I have asked the same question — five words — at every one of them. In seven of those eight countries, the answer has been silence. In the eighth, France, the answer has slowly become a different question, asked back at me. How did we miss this for so long?

One of those silent rooms was in Bordeaux in 2024. A board-certified American dermatologist was presenting a "treatment-resistant" case to forty colleagues. I asked her one question from the back row. Nobody in the room could answer it. Some of you are here because of the long Facebook post that doctor wrote afterward, describing the silence and what came next. What I want to do now is explain why the silence happens. Because it is not a coincidence that forty dermatologists could not answer my question. It is a structural feature of how dermatology is taught.

This is the part of the story that is not about one doctor or one moment. This is about why the entire field of dermatology — in seven of the eight countries I have visited — has the same blind spot.

Claudine, 59 — The Client Whose Story Made Me Start Asking Questions at American Conferences

She was a gallery owner in Nice. Her arms had changed in the autumn of 2016. By the time she came to my clinic in mid-2018, she had been to five dermatologists across Provence. Five. Each one had given her a slightly different version of the same protocol. Tretinoin. Microneedling. A peptide serum. One had even prescribed an off-label oral medication. None of them had improved her arms.

What she said to me at her first consultation has stayed with me for eight years. She said: "I have started to wonder if I am the problem. If my skin is somehow defective. Five of the most qualified people in the south of France have looked at me and told me there is nothing more they can do. At some point you stop trusting yourself."

I told her there was nothing wrong with her skin. There was something wrong with the curriculum that had trained the five doctors who failed her. They had been taught one diagnosis for crepey arms — gradual collagen decline — and they had treated her for it five times. She had a different condition. The textbooks did not contain it.

It was Claudine's case that made me start traveling to American dermatology conferences. Until that point, I had focused my work in France. After her, I started accepting invitations from European and North American practitioner exchanges, sitting in the back of rooms full of board-certified physicians, asking my one question, and watching the same silence happen. I needed to know whether the gap was French or universal. After eight countries, I have my answer. It is universal — except in France, where it is finally starting to close.

Claudine's elasticity test went from 5.6 seconds to 1.8 in eleven weeks on the three-part protocol. She wore sleeveless dresses to every gallery opening for the next year and a half. She also wrote a letter to each of the five French dermatologists who had treated her, explaining what had been missed. None of them wrote back. One of them retired six months later.

Your Body's Hormonal Collapse Creates A Skin Emergency

Here is what's actually happening four to five millimeters below the surface of your skin — in a layer called the dermis — during the months your arms change.

Your dermis is held up by a structural cushion of collagen and elastin, produced and maintained by cells called fibroblasts. These cells work constantly throughout your life. They rebuild the cushion. They repair damage. They keep the layer between your muscle and your skin surface plump, elastic, and smooth.

During perimenopause and the first two years of post-menopause, estrogen levels drop sharply. For most women, this causes the well-known 1% annual collagen decline your dermatologist can explain. But in a specific subset of women — roughly one in three post-menopausal women, based on my 38-year clinical observation — the fibroblasts don't decline. They go dormant. Like a switch turning off.

When fibroblasts go dormant, they stop producing collagen. They stop maintaining the cushion. The existing structure begins to collapse under its own weight. Two to three years' worth of gradual decline happens in three to six months.

Your arms didn't age. Your structural cushion collapsed. There's a difference. And the treatments designed for one cannot fix the other. — Anne Beaumont

This is why you look at your arms and see something that looks 20 years older than the rest of your body. The rest of your body is aging at 1% per year. Your arms experienced a structural drop-out. The timeline is completely different because the biology is completely different.

Dermatologists Mistake Sudden Collapse For Normal Aging

American dermatology has one diagnosis for crepey skin on the upper arms: age-related skin laxity. One category. One set of protocols. Prescription tretinoin. Peptide serums. Microneedling. Radiofrequency.

These are not bad treatments. They are excellent treatments for the condition they were designed for — gradual collagen decline in the epidermis, the top layer of skin. Tretinoin stimulates surface-level collagen production. Microneedling triggers wound-healing at one to two millimeters of depth. Peptide serums signal the upper dermis.

But your collapse happened at four to five millimeters of depth. Below every one of those treatments. The American protocol is aimed at the ceiling when the foundation fell.

There is a second problem. American dermatology training is funded almost entirely by pharmaceutical companies that manufacture surface treatments. Research on botanical oil penetration — the kind I've been reading in French and German journals since 2015 — is not presented at American conferences. It's not in the continuing-education curriculum. A dermatologist practicing in New York in 2026 literally does not know that sudden hormonal collapse is a separate diagnosis. Not because she's a bad physician. Because nobody has ever shown her the research.

Meanwhile, her patient spends eighteen months on tretinoin, three rounds of microneedling, and five bottles of peptide serum — roughly $3,200 — watching nothing change, while her optimal reversal window quietly closes.

European Clinics Use Different Formulations — Here's Why

In my clinic, and in clinics across France, Italy, and Germany, we've been treating sudden hormonal collapse with a specific three-part protocol for over a decade. All three parts must be present simultaneously. Miss one and the other two don't matter.

Requirement 1: Penetrate to the collapse.

To reach the dermis, a molecule must have a molecular weight under approximately 400 Daltons. Water-based creams — the kind American dermatologists prescribe — have molecular weights too high to cross the epidermal barrier. They sit on the surface. Only pure plant oils with small molecular weight can pass through. Passionfruit seed oil (molecular weight 320 Daltons) and rice bran oil (380 Daltons) are two of the few botanical oils light enough to actually reach the depth where the collapse lives.

Requirement 2: Reactivate the dormant fibroblasts.

Dormant cells don't respond to peptides or retinoids. They require specific biochemical signals — signals we've identified from botanical compounds over decades of European research. Wakame seaweed extract and White Lupin are two of the most potent. Published European studies document a 340% increase in fibroblast activity in hormonally-collapsed tissue after sustained exposure. Your fibroblasts are not dead. They are waiting to be woken up in a language they recognize.

Requirement 3: Protect the new collagen as it forms.

Here is the part that surprises every dermatologist I explain it to. When dormant fibroblasts begin producing collagen again, that new collagen is extremely fragile in hormonally-collapsed tissue. Without dermal-layer antioxidant protection, it breaks down within hours of being produced. You rebuild and lose it in the same day. Vitamin E, Açaí, and Babassu oil provide the specific antioxidant shielding new collagen needs during its first vulnerable weeks.

Then I Discovered One Company That Broke Ranks

For twelve years, I blended my own three-part formulation in small batches for clients in my clinic. I couldn't recommend anything on the retail market because every "anti-aging body oil" I tested failed at least one of the three requirements. Most had mineral oil or silicone as a base — those molecules are too large to penetrate the dermis. Others had decent carrier oils but no fibroblast reactivators. The remaining few lacked antioxidant protection, meaning any new collagen they helped build would simply break down again.

In early 2023, a small French brand called Eraé Paris sent me an unsolicited bottle of something they called Queen Oil. I was skeptical. I tested it the way I test everything: I sent the formulation documentation to an independent laboratory in Lyon.

The lab confirmed what the bottle claimed. Molecular weight 320 to 380 Daltons. Wakame and White Lupin at therapeutic concentration. Vitamin E, Açaí, and Babassu at the ratios I'd been blending by hand for a decade. No water. No silicone. No mineral oil. No fillers that block dermal absorption.

It was, to my knowledge, the first retail product on either continent that met all three requirements simultaneously.

17 Out of 20 Women Showed Measurable Reversal

I'm a clinician, not a salesperson. Before I started recommending Queen Oil to clients, I ran a 20-woman observational study in my own practice. All twenty were women between 54 and 66, diagnosed with sudden hormonal collapse at my clinic, within their optimal reversal window (defined as month 1 to month 18 from onset). Twelve weeks. Daily morning and evening application. Elasticity pinch test, skin fold measurement, and photographic documentation at weeks 0, 4, 8, and 12.

Results at week 12: 17 of 20 women showed measurable reversal on all three metrics. The average elasticity pinch dropped from 5.1 seconds to 2.7 seconds. Skin fold thickness decreased by 28%. Dermal thickness on ultrasound increased from 0.7mm to 1.0mm average.

Three women — all of whom had been past month 20 at the start of the study — showed partial improvement but didn't reach full reversal. This is consistent with what I'd been observing for years: there is a window, and it closes.

I just tried on a sleeveless dress I haven't worn in a year. I forgot what it felt like to look at my own arms without flinching. — Client, week 8

My neighbor asked what I'd done. She said I look five years younger. I haven't done anything to my face. It's because I'm standing differently — I'm not hiding anymore. — Client, week 10

What Makes Queen Oil Different From Everything Else

Where Can I Get Queen Oil?

Eraé sells Queen Oil directly from their site. They do not sell through Amazon, Sephora, or any third-party retailer — partly to control quality, partly because they keep having to pull the product when batches sell out. At the time I'm writing this, the last three batches have each sold out in under a week.

I've been told there's a feature coming next month in a major American women's magazine that will almost certainly collapse the inventory entirely for several weeks. If you're reading this before that happens, you will have an easier time getting a bottle than the women who find this article after.

The numbers above are the percentage of women who show full reversal within twelve weeks, grouped by how long they've been living with sudden hormonal collapse before starting treatment. They are not predictions. They are observed outcomes from my clinic and from the European research I've been reading for a decade.

The reason the window closes is biological: dormant fibroblasts that go un-stimulated for more than two years begin to adapt to the dormant state. They lose their capacity to be reactivated. At that point, the treatment options become much more limited and much more invasive.

If you are in month 4 or month 8 or month 14, you have room to act. If you are in month 22, you are running out of time. If you are past month 25, the protocol still helps — but the odds drop significantly. I will not mislead you about that.